{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:27:36Z","timestamp":1772616456615,"version":"3.50.1"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Background<\/jats:title>Patients with cancer seen in rural and underserved areas disproportionately face barriers to access genetic services. Genetic testing is critical to inform treatment decisions, for early detection of another cancer, and to identify at-risk family members who may benefit from screening and prevention.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine medical oncologists\u2019 genetic testing ordering trends for patients with cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective quality improvement study was performed in 2 phases over 6 months between August 1, 2020, and January 31, 2021, at a community network hospital. Phase 1 focused on observation of clinic processes. Phase 2 incorporated peer coaching from cancer genetics experts for medical oncologists at the community network hospital. The follow-up period lasted 9 months.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The number of genetic tests ordered was compared between phases.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 634 patients (mean [SD] age, 71.0 [10.8] years [range, 39-90 years]; 409 women [64.5%]; 585 White [92.3%]); 353 (55.7%) had breast cancer, 184 (29.0%) had prostate cancer, and 218 (34.4%) had a family history of cancer. Of the 634 patients with cancer, 29 of 415 (7.0%) received genetic testing in phase 1, and 25 of 219 (11.4%) received genetic testing in phase 2. Of the 29 patients who received testing in phase 1, 20 (69.0%) had germline genetic testing; 23 of 25 patients (92.0%) had germline genetic testing in phase 2. Uptake of germline genetic testing increased by 23.0% between phases, but the difference was not statistically significant (P<\/jats:italic>\u2009=\u2009.06). Uptake of germline genetic testing was highest among patients with pancreatic cancer (4 of 19 [21.1%]) and ovarian cancer (6 of 35 [17.1%]); the National Comprehensive Cancer Network (NCCN) recommends offering genetic testing to all patients with pancreatic cancer and ovarian cancer.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study suggests that peer coaching from cancer genetics experts was associated with an increase in ordering of genetic testing by medical oncologists. Efforts made to (1) standardize gathering of personal and family history of cancer, (2) review biomarker data suggestive of a hereditary cancer syndrome, (3) facilitate ordering tumor and\/or germline genetic testing every time NCCN criteria are met, (4) encourage data sharing between institutions, and (5) advocate for universal coverage for genetic testing may help realize the benefits associated with precision oncology for patients and their families seeking care at community cancer centers.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.1723","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:02:13Z","timestamp":1678118533000},"page":"e231723","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of a Peer Physician Coaching Partnership Between a Designated Cancer Center Genetics Service and a Community Cancer Network Hospital"],"prefix":"10.1001","volume":"6","author":[{"given":"Lauren G.","family":"Santos","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"Clinical Cancer Genetics Service, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Buzdnitskaya","sequence":"additional","affiliation":[{"name":"Olympic Medical Cancer Center, Sequim, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley A.","family":"Rolf","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Souza","sequence":"additional","affiliation":[{"name":"Olympic Medical Cancer Center, Sequim, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sienko","sequence":"additional","affiliation":[{"name":"Olympic Medical Cancer Center, Sequim, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Alberto","family":"Ruiz-Bonilla","sequence":"additional","affiliation":[{"name":"Olympic Medical Cancer Center, Sequim, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binay","family":"Shah","sequence":"additional","affiliation":[{"name":"Olympic Medical Cancer Center, Sequim, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Jewell","sequence":"additional","affiliation":[{"name":"Olympic Medical Cancer Center, Sequim, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Jensen","sequence":"additional","affiliation":[{"name":"Olympic Medical Cancer Center, Sequim, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Horike-Pyne","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo Ann","family":"Elrod","sequence":"additional","affiliation":[{"name":"Clinical Cancer Genetics Service, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennie","family":"Crews","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"Clinical Cancer Genetics Service, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercy","family":"Laurino","sequence":"additional","affiliation":[{"name":"Clinical Cancer Genetics Service, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin Austin","family":"Weeks","sequence":"additional","affiliation":[{"name":"Olympic Medical Cancer Center, Sequim, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne E.","family":"Dubard-Gault","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"Clinical Cancer Genetics Service, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"issue":"2","key":"zoi230083r1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3798\/tia.1937-0237.2109","article-title":"Health disparities and access to healthcare in rural vs urban areas.","volume":"14","author":"Reilly","year":"2021","journal-title":"Theory Action"},{"issue":"24","key":"zoi230083r2","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.20.03661","article-title":"Therapeutic implications of germline testing in patients with advanced cancers.","volume":"39","author":"Stadler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi230083r3","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jamaoncol.2020.2059","article-title":"Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer.","volume":"6","author":"Hadar","year":"2020","journal-title":"JAMA Oncol"},{"issue":"23","key":"zoi230083r4","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"zoi230083r5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/jpm9020026","article-title":"Exploring predictors of genetic counseling and testing for hereditary breast and ovarian cancer: findings from the 2015 U.S. National Health Interview Survey.","volume":"9","author":"Allen","year":"2019","journal-title":"J Pers Med"},{"issue":"4","key":"zoi230083r6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10897-016-0040-0","article-title":"Why is cancer genetic counseling underutilized by women identified as at risk for hereditary breast cancer? patient perceptions of barriers following a referral letter.","volume":"26","author":"Kne","year":"2017","journal-title":"J Genet Couns"},{"issue":"15","key":"zoi230083r7","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.20.02785","article-title":"Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019.","volume":"39","author":"Kurian","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi230083r9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10549-016-4003-9","article-title":"Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.","volume":"160","author":"Graffeo","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"zoi230083r10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing.","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"issue":"26","key":"zoi230083r11","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"zoi230083r12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cancergen.2017.09.003","article-title":"Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories.","volume":"218-219","author":"Rosenthal","year":"2017","journal-title":"Cancer Genet"},{"issue":"4","key":"zoi230083r13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41436-018-0277-0","article-title":"Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.","volume":"21","author":"Rowley","year":"2019","journal-title":"Genet Med"},{"issue":"15","key":"zoi230083r19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS5098","article-title":"The GENTleMEN study: genetic testing for men with metastatic prostate cancer in Washington state and beyond.","volume":"36","author":"Cheng","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi230083r21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome.","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi230083r22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/1055-9965.EPI-21-0820","article-title":"Multiple primary cancers in patients undergoing tumor-normal sequencing define novel associations.","volume":"31","author":"Liu","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"zoi230083r23","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/jamia\/ocaa152","article-title":"Electronic health records contain dispersed risk factor information that could be used to prevent breast and ovarian cancer.","volume":"27","author":"Payne","year":"2020","journal-title":"J Am Med Inform Assoc"},{"key":"zoi230083r8","volume-title":"Understanding Disparities in Access to Genomic Medicine: Proceedings of a Workshop","year":"2018"},{"key":"zoi230083r14","volume-title":"NCCN Guidelines for Patients: Pancreatic Cancer","author":"National Comprehensive Cancer Network","year":"2020"},{"key":"zoi230083r17","volume-title":"NCCN Guidelines for Patients: Ovarian Cancer","author":"National Comprehensive Cancer Network","year":"2020"},{"key":"zoi230083r18","volume-title":"Optimal Resources for Cancer Care: 2020 Standards","author":"American College of Surgeons","year":"2019"},{"key":"zoi230083r15","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. Accessed May 11, 2022. https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants"},{"key":"zoi230083r16","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. Version 1.2022\u2014August 11, 2021. Accessed January 29, 2023. https:\/\/www.mygenecounsel.com\/wp-content\/uploads\/2022\/03\/NCCN-Guidelines.pdf"},{"key":"zoi230083r20","unstructured":"United States Census Bureau. QuickFacts: Seattle city, Washington; Sequim city, Washington. Accessed May 11, 2022. https:\/\/www.census.gov\/quickfacts\/fact\/table\/seattlecitywashington,sequimcitywashington\/PST045221"},{"key":"zoi230083r24","unstructured":"The HIPAA Guide. HIPAA compliance guide. Accessed May 25, 2022. https:\/\/www.hipaaguide.net\/hipaa-compliance-guide"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2801998\/santos_2023_oi_230083_1677090448.79873.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:02:20Z","timestamp":1678118540000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2801998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.1723","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]}}}